<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930202</url>
  </required_header>
  <id_info>
    <org_study_id>35774-A</org_study_id>
    <nct_id>NCT00930202</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury</brief_title>
  <official_title>Open Label Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to utilize conivaptan (Vaprisol) to promote isolated water loss, in
      combination with normal (physiologic) fluid replacement to maintain a normal blood volume
      status, in patients with severe TBI. The goal of this therapy is to raise blood sodium in a
      controlled fashion in subjects with severe TBI, and reduce the use of hypertonic saline
      infusion. We hypothesize that this therapy will maintain a stable state of high blood sodium,
      while decreasing the overall sodium load needed to achieve these goals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of events of excessive rate of increase in sodium levels (&gt;1 mEq/hr).</measure>
    <time_frame>Every 4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile: number of events of increased serum sodium levels above the intended target range, and any adverse events occurring during the study period.</measure>
    <time_frame>Hospital Stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium load: Sodium load is defined as the cumulative amount of sodium administered by enteral and parenteral routes from the time of randomization to 48 hours post-randomization</measure>
    <time_frame>Until 48 hours post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum sodium stability: a. Stable state of hypernatremia b. Sodium variability c. Time to achievement of target sodium levels after randomization</measure>
    <time_frame>Until 48 hours post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>Until 48 hours post randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral edema: a. Mean ICP in the first 48 hours after randomization b. Reduction of cerebral edema</measure>
    <time_frame>Until 48 hours post randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Severe Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Conivaptan (Vaprisol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan (Vaprisol)</intervention_name>
    <description>Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.</description>
    <arm_group_label>Conivaptan (Vaprisol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or greater

          -  Initial diagnosis of an isolated, severe traumatic brain injury (Glasgow Coma Score of
             8 or less upon initial evaluation)

          -  Cerebral edema with a head CT and Marshall classification of diffuse injury type II,
             III, or IV.

          -  Primary care team orders to raise blood sodium by 10 mEq/L from baseline.

          -  Placement of an intraparenchymal fiberoptic monitor to monitor intracranial pressure
             (ICP).

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Signs of hypovolemia including systolic BP &lt; 90 mmHg

          -  Signs of liver disease including jaundice and ascites

               -  AST &gt; 35 units/L

               -  ALT &gt; 35 units/L

          -  Signs of renal disease including history of dialysis

               -  Serum creatinine &gt; 1.5 mg/dL

               -  BUN &gt; 20 mg/dL range

          -  Baseline serum sodium &gt;/= 145 mEq/L

          -  Pregnant or lactating females

          -  Concomitant use of digoxin, ketoconazole, itraconazole, clarithromycin, ritonavir,
             indinavir, simvastatin and lovastatin

          -  Presentation to the tertiary care hospital &gt; 24 hours post-injury

          -  Multi-system traumatic injuries

          -  Diabetes Insipidus

          -  Anticipation of diagnosis compatible with brain death, or no expectation of survival
             with 48 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Treggiari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Miriam Treggiari, Associate Professor of Anesthesiology &amp; Pain Medicine</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Conivaptan</keyword>
  <keyword>Vaprisol</keyword>
  <keyword>Sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

